Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).
News story | IDegLira delays need for treatment intensification over glargine
News story | Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes
News story | Real-world data confirm benefits of IDegLira